Charles River Laboratories International (NYSE:CRL) Issues FY 2026 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 11.450-11.450 for the period, compared to the consensus estimate of 11.330. The company issued revenue guidance of $3.9 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion.

Charles River Laboratories International Stock Down 2.7%

Shares of NYSE:CRL opened at $277.44 on Thursday. The business has a fifty day simple moving average of $267.76 and a 200 day simple moving average of $211.63. Charles River Laboratories International has a 12-month low of $144.26 and a 12-month high of $303.30. The firm has a market cap of $13.24 billion, a P/E ratio of -57.20, a P/E/G ratio of 2.80 and a beta of 1.40. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. During the same quarter in the prior year, the firm posted $3.12 EPS. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Analysts predict that Charles River Laboratories International will post 11.33 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CRL has been the topic of a number of research analyst reports. Weiss Ratings raised shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. CLSA cut Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 target price for the company. in a research note on Monday, July 20th. BNP Paribas Exane set a $250.00 price objective on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. Morgan Stanley raised their price target on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, JPMorgan Chase & Co. upgraded shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $180.00 to $310.00 in a report on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $273.81.

Insider Activity at Charles River Laboratories International

In other news, CEO Birgit Girshick sold 6,500 shares of Charles River Laboratories International stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total value of $1,819,350.00. Following the completion of the transaction, the chief executive officer directly owned 36,013 shares in the company, valued at approximately $10,080,038.70. The trade was a 15.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon Parisotto sold 2,039 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $294.12, for a total transaction of $599,710.68. Following the completion of the transaction, the executive vice president directly owned 4,807 shares in the company, valued at approximately $1,413,834.84. The trade was a 29.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 165,990 shares of company stock worth $42,606,388 in the last ninety days. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.